Prostate Cancer Trial, Recruiting NCT06866782 Sponsor: Fundacio Puigvert Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT06866782
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults who are male and aged 18 or older, with no upper age limit
  • People who have been diagnosed with prostate cancer confirmed through a tissue sample (biopsy)
  • People who need imaging scans to check for signs of cancer spread, either at the time of first diagnosis or after cancer has returned or progressed following earlier treatment
  • People who agree to take part and sign a written consent form

Who may not be able to join:

  • People who are already taking part in another study that uses a type of advanced imaging (called Next-Generation Imaging) to check for cancer spread
  • People who have another significant health condition that, in the opinion of the doctor running the trial, makes participation unsuitable (confirm with trial site)
  • People who are unlikely to be able to complete the full study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Francesco Sanguedolce, MD, PhD, Fundació Puigvert

Phone: +34934169100

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Fundacio Puigvert
Registry
ClinicalTrials.gov
Start date
17 September 2024
Est. completion
23 December 2025

Where this trial is recruiting

🇧🇪 Belgium 🇫🇷 France 🇩🇪 Germany 🇮🇹 Italy 🇳🇱 Netherlands 🇵🇱 Poland 🇪🇸 Spain 🇸🇪 Sweden

Primary endpoints

Proportion of patients requiring NGI, conventional imaging, or a combination of both imaging tools.; Proportion of patients with a change of treatment determined by the imaging test result, when multiple imaging tests have been realized

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov